M Poyurovsky

Summary

Affiliation: Technion-Israel Institute of Technology
Country: Israel

Publications

  1. ncbi request reprint Preferential aggregation of obsessive-compulsive spectrum disorders in schizophrenia patients with obsessive-compulsive disorder
    Michael Poyurovsky
    Research Unit, Tirat Carmel Mental Health Center, Israel
    Can J Psychiatry 51:746-54. 2006
  2. doi request reprint Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination
    Michael Poyurovsky
    Research Unit, Tirat Carmel Mental Health Center, POB 9, Tirat Carmel 30200, Israel
    Psychopharmacology (Berl) 226:615-22. 2013
  3. doi request reprint Obsessive-compulsive symptoms in schizophrenia: implications for future psychiatric classifications
    Michael Poyurovsky
    Tirat Carmel Mental Health Center, Tirat Carmel 30200, Israel
    Compr Psychiatry 53:480-3. 2012
  4. ncbi request reprint The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients
    Michael Poyurovsky
    Research Unit, Tirat Carmel Mental Health Center, Tirat Carmel, Israel
    Int Clin Psychopharmacol 20:101-3. 2005
  5. ncbi request reprint Obsessive-compulsive disorder (OCD) with schizotypy vs. schizophrenia with OCD: diagnostic dilemmas and therapeutic implications
    M Poyurovsky
    Research Unit, Tirat Carmel Mental Health Center and Rappaport Faculty of Medicine, Israel Institute of Technology, Technion, 9 Eshkol Street, Haifa, Tirat Carmel 30200, Israel
    J Psychiatr Res 39:399-408. 2005
  6. ncbi request reprint Obsessive-compulsive disorder in elderly schizophrenia patients
    Michael Poyurovsky
    Research Unit, Tirat Carmel Mental Health Center, 9 Eshkol St, Tirat Carmel 30200, Israel
    J Psychiatr Res 40:189-91. 2006
  7. ncbi request reprint Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial
    Michael Poyurovsky
    Research Unit, Tirat Carmel Mental Health Center, Tirat Carmel, Israel
    Biol Psychiatry 59:1071-7. 2006
  8. ncbi request reprint Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study
    Michael Poyurovsky
    Research Unit, Tirat Carmel Mental Health Center, P O Box 9, Tirat Carmel, 30200, Israel
    Psychopharmacology (Berl) 192:441-8. 2007
  9. ncbi request reprint Neurological soft signs in schizophrenia patients with obsessive-compulsive disorder
    Michael Poyurovsky
    Research Unit, Tirat Carmel Mental Health Center, 9 Eshkol Street, Tirat Carmel 30200, Israel
    J Neuropsychiatry Clin Neurosci 19:145-50. 2007
  10. ncbi request reprint Awareness of illness and insight into obsessive-compulsive symptoms in schizophrenia patients with obsessive-compulsive disorder
    Michael Poyurovsky
    Research Unit, Tirat Carmel Mental Health Center, Tirat Carmel, Israel
    J Nerv Ment Dis 195:765-8. 2007

Collaborators

Detail Information

Publications37

  1. ncbi request reprint Preferential aggregation of obsessive-compulsive spectrum disorders in schizophrenia patients with obsessive-compulsive disorder
    Michael Poyurovsky
    Research Unit, Tirat Carmel Mental Health Center, Israel
    Can J Psychiatry 51:746-54. 2006
    ..To validate a complex association between schizophrenia and obsessive-compulsive disorder (OCD)...
  2. doi request reprint Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination
    Michael Poyurovsky
    Research Unit, Tirat Carmel Mental Health Center, POB 9, Tirat Carmel 30200, Israel
    Psychopharmacology (Berl) 226:615-22. 2013
    ..In the present placebo-controlled study, we evaluated whether a reboxetine-betahistine combination attenuates olanzapine-induced weight gain in schizophrenia patients...
  3. doi request reprint Obsessive-compulsive symptoms in schizophrenia: implications for future psychiatric classifications
    Michael Poyurovsky
    Tirat Carmel Mental Health Center, Tirat Carmel 30200, Israel
    Compr Psychiatry 53:480-3. 2012
    ..The authors highlight the clinical significance of obsessive-compulsive symptoms in schizophrenia, provide diagnostic criteria for "schizo-obsessive" patients and address future directions for research...
  4. ncbi request reprint The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients
    Michael Poyurovsky
    Research Unit, Tirat Carmel Mental Health Center, Tirat Carmel, Israel
    Int Clin Psychopharmacol 20:101-3. 2005
    ..Our findings justify a placebo-controlled evaluation of the putative weight-attenuating effect of betahistine in olanzapine-induced weight gain...
  5. ncbi request reprint Obsessive-compulsive disorder (OCD) with schizotypy vs. schizophrenia with OCD: diagnostic dilemmas and therapeutic implications
    M Poyurovsky
    Research Unit, Tirat Carmel Mental Health Center and Rappaport Faculty of Medicine, Israel Institute of Technology, Technion, 9 Eshkol Street, Haifa, Tirat Carmel 30200, Israel
    J Psychiatr Res 39:399-408. 2005
    ....
  6. ncbi request reprint Obsessive-compulsive disorder in elderly schizophrenia patients
    Michael Poyurovsky
    Research Unit, Tirat Carmel Mental Health Center, 9 Eshkol St, Tirat Carmel 30200, Israel
    J Psychiatr Res 40:189-91. 2006
    ..We conclude that OCD is not rare in elderly schizophrenia patients. Identification of this potentially treatable condition is imperative to provide adequate care...
  7. ncbi request reprint Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial
    Michael Poyurovsky
    Research Unit, Tirat Carmel Mental Health Center, Tirat Carmel, Israel
    Biol Psychiatry 59:1071-7. 2006
    ..We investigated the antiakathisia effect, safety, and tolerability of low-dose mirtazapine, an agent with marked 5-HT(2A) antagonism...
  8. ncbi request reprint Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study
    Michael Poyurovsky
    Research Unit, Tirat Carmel Mental Health Center, P O Box 9, Tirat Carmel, 30200, Israel
    Psychopharmacology (Berl) 192:441-8. 2007
    ..In the present study, we sought to replicate our preliminary findings, which indicated that coadministration of the selective norepinephrine reuptake inhibitor reboxetine attenuates olanzapine-induced weight gain...
  9. ncbi request reprint Neurological soft signs in schizophrenia patients with obsessive-compulsive disorder
    Michael Poyurovsky
    Research Unit, Tirat Carmel Mental Health Center, 9 Eshkol Street, Tirat Carmel 30200, Israel
    J Neuropsychiatry Clin Neurosci 19:145-50. 2007
    ..However, they are of limited value as a putative endophenotype in a search for specific etiological mechanisms underlying a schizo-obsessive subgroup of schizophrenia...
  10. ncbi request reprint Awareness of illness and insight into obsessive-compulsive symptoms in schizophrenia patients with obsessive-compulsive disorder
    Michael Poyurovsky
    Research Unit, Tirat Carmel Mental Health Center, Tirat Carmel, Israel
    J Nerv Ment Dis 195:765-8. 2007
    ..Our findings indicate that OCS in schizophrenia represent an identifiable dimension of psychopathology independent of core schizophrenia symptoms...
  11. doi request reprint Clinical characteristics of schizotypal-related obsessive-compulsive disorder
    Michael Poyurovsky
    Research Unit, Tirat Carmel Mental Health Center, Tirat Carmel, Israel
    Psychiatry Res 159:254-8. 2008
    ..A distinct clinical phenotype of OCD associated with SPD should be considered when investigating etiopathogenetic mechanisms...
  12. doi request reprint Comparison of clinical characteristics, co-morbidity and pharmacotherapy in adolescent schizophrenia patients with and without obsessive-compulsive disorder
    Michael Poyurovsky
    Tirat Carmel Mental Health Center, Tirat Carmel, Israel
    Psychiatry Res 159:133-9. 2008
    ..The neurobiology underlying the co-occurrence of the OC and schizophrenia symptoms merits further evaluation...
  13. doi request reprint Lamotrigine augmentation in schizophrenia and schizoaffective patients with obsessive-compulsive symptoms
    M Poyurovsky
    Research Unit, Tirat Carmel Mental Health Center, Rappaport Faculty of Medicine, Israel Institute of Technology Technion, Haifa, Israel
    J Psychopharmacol 24:861-6. 2010
    ..69, P = 0.04). Lamotrigine was safe and well tolerated. Explicit evaluation of therapeutic efficacy of adjunctive lamotrigine in schizoaffective disorder patients with comorbid OCS merits further investigation...
  14. ncbi request reprint Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an add-on, double-blind placebo-controlled study
    Michael Poyurovsky
    Tirat Carmel Mental Health Center, Tirat Carmel, Israel
    Isr J Psychiatry Relat Sci 46:213-20. 2009
    ..g., atomoxetine) are needed to determine the role of NRIs as cognitive enhancers in patients with schizophrenia and other disorders associated with cognitive impairments...
  15. ncbi request reprint Familial aggregation of schizophrenia-spectrum disorders and obsessive-compulsive associated disorders in schizophrenia probands with and without OCD
    Michael Poyurovsky
    Research Unit, Tirat Carmel Mental Health Center, Tirat Carmel, Israel
    Am J Med Genet B Neuropsychiatr Genet 133:31-6. 2005
    ....
  16. ncbi request reprint Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment
    Michael Poyurovsky
    Tirat Carmel Mental Health Center, Tirat Carmel, Israel
    CNS Drugs 18:989-1010. 2004
    ..Finally, future directions of research in schizophrenia-OCD comorbidity relevant to clinical practice are discussed...
  17. ncbi request reprint Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition
    Michael Poyurovsky
    Research Unit, Tirat Carmel Mental Health Center, Israel
    Am J Psychiatry 159:1058-60. 2002
    ....
  18. ncbi request reprint Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study
    Michael Poyurovsky
    Tirat Carmel Mental Health Center, Israel
    Am J Psychiatry 160:297-302. 2003
    ....
  19. ncbi request reprint The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study
    Michael Poyurovsky
    Research Unit, Tirat Carmel Mental Health Center, 9 Eshkol Street, 30200 Tirat Carmel, Israel
    Eur Neuropsychopharmacol 14:332-6. 2004
    ..In conclusion, famotidine (40 mg/day for 6 weeks) is not effective in preventing/attenuating weight gain in olanzapine-treated first-episode schizophrenia patients...
  20. ncbi request reprint Obsessive-compulsive disorder in bipolar disorder patients with first manic episode
    Artashez Pashinian
    Research Unit, Tirat Carmel Mental Health Center, Tirat Carmel, Israel
    J Affect Disord 94:151-6. 2006
    ..To control for these factors we evaluated the prevalence of OCD in patients with first-episode acute mania who met DSM-IV criteria for BD-I, and compared them with our previously reported group of first-episode schizophrenia patients...
  21. ncbi request reprint Insight into obsessive-compulsive symptoms and awareness of illness in adolescent schizophrenia patients with and without OCD
    Sarit Faragian
    Research Unit, Tirat Carmel Mental Health Center, POB 9, Tirat Carmel 30200, Israel
    Child Psychiatry Hum Dev 39:39-48. 2008
    ..Early identification of this potentially treatable syndrome is imperative for appropriate diagnosis and treatment of this unique subset of schizophrenia patients...
  22. ncbi request reprint Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebo-controlled pilot study
    Michael Poyurovsky
    Research Unit, Tirat Carmel Mental Health Center, 9 Eshkol Street, Tirat Carmel 30200, Israel
    J Clin Psychopharmacol 23:305-8. 2003
    ..Marked 5HT2A/2C antagonistic activity of mirtazapine apparently accounts for its anti-NIA activity. The role of mirtazapine in the treatment of akathisia induced by atypical antipsychotic agents merits further investigation...
  23. ncbi request reprint Comparison of clinical characteristics and comorbidity in schizophrenia patients with and without obsessive-compulsive disorder: schizophrenic and OC symptoms in schizophrenia
    Michael Poyurovsky
    Research Unit, Tirat Carmel Mental Health Center, Tirat Carmel, Israel
    J Clin Psychiatry 64:1300-7. 2003
    ..Since a substantial proportion of schizophrenia patients has symptoms of obsessive-compulsive disorder (OCD), we sought to provide a phenomenological characterization of a schizophrenia subgroup with OCD...
  24. ncbi request reprint Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study
    H Silver
    Clinical Research Unit, Flugelman Mazra Psychiatric Hospital, Doar Na Ashrat Acco, Israel
    Int Clin Psychopharmacol 15:257-61. 2000
    ..The combination was well tolerated. Fluvoxamine augmentation of antipsychotics is safe in chronic schizophrenic patients with mixed positive and negative symptoms and may ameliorate negative symptoms in such patients...
  25. ncbi request reprint Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study
    Michael Poyurovsky
    Tirat Carmel Mental Health Center, 9 Eshkol Street, 30200, Tirat Carmel, Israel
    Eur Neuropsychopharmacol 13:123-8. 2003
    ..The mianserin group overperformed the placebo group on selective ANAM memory/learning tests, reflected in moderate-to-high effect size values. No between-group differences were revealed in WCST and clinical ratings...
  26. ncbi request reprint Obsessive-compulsive disorder in hospitalized patients with chronic schizophrenia
    M Poyurovsky
    Tirat Carmel Mental Health Center, Tirat Carmel, Israel
    Psychiatry Res 102:49-57. 2001
    ....
  27. doi request reprint Obsessive-compulsive symptom dimensions in schizophrenia patients with comorbid obsessive-compulsive disorder
    Sarit Faragian
    Research Unit, Tirat Carmel Mental Health Center, P O Box 9, Tirat Carmel 30200, Israel
    Prog Neuropsychopharmacol Biol Psychiatry 33:1009-12. 2009
    ..The five symptom dimensions are comparable to those revealed in "pure" OCD, and suggest the involvement of universal mechanisms in the pathogenesis of OCD regardless of the presence of schizophrenia...
  28. ncbi request reprint The neuropsychological basis of competence to consent in first-episode schizophrenia: a pilot metacognitive study
    Danny Koren
    Psychology Department, University of Haifa, Technion Medical School, Haifa, Israel
    Biol Psychiatry 57:609-16. 2005
    ..This study was designed to explore the neuropsychological basis of competence to consent to treatment in first-episode schizophrenia by evaluating its differential and joint links with cognitive versus metacognitive performance...
  29. ncbi request reprint COMT Val158Met polymorphism in schizophrenia with obsessive-compulsive disorder: a case-control study
    Michael Poyurovsky
    Tirat HaCarmel Mental Health Center, Tirat Carmel, Israel
    Neurosci Lett 389:21-4. 2005
    ..These results do not support the hypothesis that the COMT Val158Met gene polymorphism is associated with liability to schizophrenia-OCD...
  30. ncbi request reprint The neuropsychological basis of insight in first-episode schizophrenia: a pilot metacognitive study
    Danny Koren
    Psychology Department, University of Haifa, Haifa 31905, Israel
    Schizophr Res 70:195-202. 2004
    ..These preliminary results suggest that metacognition is an important mediator between basic cognitive deficits and poor insight, and might be even more relevant to poor insight than cognitive deficits per se...
  31. ncbi request reprint [Adherence to antipsychotic medication in schizophrenia patients]
    Vered Baloush-Kleinman
    School of Social Work, Tel Aviv University
    Harefuah 141:1042-9, 1090. 2002
    ..In addition, we describe a modified health-belief model that may facilitate better understanding of empirical findings. Therapeutic interventions to encourage better treatment compliance are discussed...
  32. ncbi request reprint Memantine for treatment-resistant OCD
    Michael Poyurovsky
    Am J Psychiatry 162:2191-2. 2005
  33. doi request reprint Aripiprazole's receptor pharmacology and extrapyramidal side effects
    Michael Poyurovsky
    Am J Psychiatry 165:398; author reply 398-9. 2008
  34. ncbi request reprint Obsessive-compulsive disorder in adolescent schizophrenia patients
    Allon Nechmad
    Adolescent Inpatient Department, Shalvata Mental Health Center, Hod Hasharon, Israel
    Am J Psychiatry 160:1002-4. 2003
    ..However, the rate of OCD comorbidity in adolescent schizophrenia patients has yet to be systematically evaluated...
  35. ncbi request reprint Mianserin for the rapid improvement of chronic akathisia in a schizophrenia patient
    Rafael Stryjer
    Eur Psychiatry 19:237-8. 2004
  36. ncbi request reprint Treatment of neuroleptic-induced akathisia with the 5-HT2A antagonist trazodone
    Rafael Stryjer
    Beer Yaakov Mental Health Center, Israel
    Clin Neuropharmacol 26:137-41. 2003
    ..Further study in the context of a double-blind, placebo-controlled trial is mandated to substantiate these preliminary findings...
  37. ncbi request reprint Olanzapine-sertraline combination in schizophrenia with obsessive-compulsive disorder
    Michael Poyurovsky
    J Clin Psychiatry 64:611. 2003